FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976547998> ?p ?o ?g. }

• W1976547998 endingPage "794" @default.
• W1976547998 startingPage "790" @default.
• W1976547998 abstract "Since July 1, 2006 bone mineral density (BMD) testing has been reimbursed for osteoporosis screening under specific clinical conditions in France. Concurrently, drug coverage has been extended to all anti-osteoporotic treatments in women with low BMD. It was thus expected that the utilisation of BMD testing and subsequent treatment would increase significantly.To examine the pattern of use of BMD testing following reimbursement by the French National Health Insurance and subsequent prescriptions reimbursed for anti-osteoporotic treatment in the general population of the Rhone-Alpes area, France.Time trends, age and sex distribution of the population, and specialty of the physicians who performed the test were examined from all physicians' claims for BMD testing between 2006 and 2009 in Rhone-Alpes. A prospective inception cohort of all women aged 50 years and older, without prior reimbursement for anti-osteoporotic treatment and who had a BMD test between January 1, 2007 and March 31, 2007, was then created. Women were followed for 1 year for their reimbursements of estrogen or other anti-osteoporotic treatment (bisphosphonates, raloxifene, teriparatide and strontium ranelate) after their initial BMD test.Between July 2006 and August 2009, 140,038 BMD tests were reimbursed in Rhone-Alpes, France, among which 94.8% were performed in women aged 50 years and older. In women, the number of BMD tests tended to significantly decrease during the study period (p for trend=0.047). The inception cohort was composed of 9635 women without prior anti-osteoporotic treatment. Among women without prior estrogen treatment, 27.3% (n=2339) initiated an anti-osteoporotic treatment within 4 months after a BMD test, mostly with bisphosphonates (16.8% n=1441), followed by strontium ranelate (5.8% n=498) and raloxifene (3.4% n=290). At 1 year 1702 women (71.7%) were still on treatment.Following the decision by the French National Health Insurance of repayment of BMD measurement, the proportion of women who had BMD testing tended to decrease instead of increase over the time period. Although BMD screening is focused in France on high risk women, only 25% of those who had an initial BMD test were subsequently treated with an anti-osteoporotic medication." @default.
• W1976547998 created "2016-06-24" @default.
• W1976547998 creator A5017741794 @default.
• W1976547998 creator A5024064782 @default.
• W1976547998 creator A5036528950 @default.
• W1976547998 creator A5036768799 @default.
• W1976547998 creator A5055448593 @default.
• W1976547998 creator A5071199150 @default.
• W1976547998 date "2010-10-01" @default.
• W1976547998 modified "2023-09-25" @default.
• W1976547998 title "Has reimbursement of bone mineral density testing and anti-osteoporotic treatments improved management of osteoporosis in France?" @default.
• W1976547998 cites W1967700838 @default.
• W1976547998 cites W1982331048 @default.
• W1976547998 cites W1986071122 @default.
• W1976547998 cites W2007367416 @default.
• W1976547998 cites W2021641144 @default.
• W1976547998 cites W2021914683 @default.
• W1976547998 cites W2037457242 @default.
• W1976547998 cites W2040340391 @default.
• W1976547998 cites W2057872084 @default.
• W1976547998 cites W2060370055 @default.
• W1976547998 cites W2060599344 @default.
• W1976547998 cites W2085064249 @default.
• W1976547998 cites W2108063837 @default.
• W1976547998 cites W2127071635 @default.
• W1976547998 cites W2133228717 @default.
• W1976547998 cites W2142839426 @default.
• W1976547998 cites W2149863178 @default.
• W1976547998 cites W37910291 @default.
• W1976547998 cites W2509551379 @default.
• W1976547998 doi "https://doi.org/10.1016/j.bone.2010.06.026" @default.
• W1976547998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20601300" @default.
• W1976547998 hasPublicationYear "2010" @default.
• W1976547998 type Work @default.
• W1976547998 sameAs 1976547998 @default.
• W1976547998 citedByCount "10" @default.
• W1976547998 countsByYear W19765479982012 @default.
• W1976547998 countsByYear W19765479982013 @default.
• W1976547998 countsByYear W19765479982014 @default.
• W1976547998 countsByYear W19765479982015 @default.
• W1976547998 countsByYear W19765479982016 @default.
• W1976547998 crossrefType "journal-article" @default.
• W1976547998 hasAuthorship W1976547998A5017741794 @default.
• W1976547998 hasAuthorship W1976547998A5024064782 @default.
• W1976547998 hasAuthorship W1976547998A5036528950 @default.
• W1976547998 hasAuthorship W1976547998A5036768799 @default.
• W1976547998 hasAuthorship W1976547998A5055448593 @default.
• W1976547998 hasAuthorship W1976547998A5071199150 @default.
• W1976547998 hasConcept C121608353 @default.
• W1976547998 hasConcept C126322002 @default.
• W1976547998 hasConcept C160735492 @default.
• W1976547998 hasConcept C162324750 @default.
• W1976547998 hasConcept C1862650 @default.
• W1976547998 hasConcept C2776541429 @default.
• W1976547998 hasConcept C2776594446 @default.
• W1976547998 hasConcept C2776886416 @default.
• W1976547998 hasConcept C2777308945 @default.
• W1976547998 hasConcept C2779703844 @default.
• W1976547998 hasConcept C2779889926 @default.
• W1976547998 hasConcept C2908647359 @default.
• W1976547998 hasConcept C50522688 @default.
• W1976547998 hasConcept C530470458 @default.
• W1976547998 hasConcept C71924100 @default.
• W1976547998 hasConcept C72563966 @default.
• W1976547998 hasConcept C84606932 @default.
• W1976547998 hasConcept C99454951 @default.
• W1976547998 hasConceptScore W1976547998C121608353 @default.
• W1976547998 hasConceptScore W1976547998C126322002 @default.
• W1976547998 hasConceptScore W1976547998C160735492 @default.
• W1976547998 hasConceptScore W1976547998C162324750 @default.
• W1976547998 hasConceptScore W1976547998C1862650 @default.
• W1976547998 hasConceptScore W1976547998C2776541429 @default.
• W1976547998 hasConceptScore W1976547998C2776594446 @default.
• W1976547998 hasConceptScore W1976547998C2776886416 @default.
• W1976547998 hasConceptScore W1976547998C2777308945 @default.
• W1976547998 hasConceptScore W1976547998C2779703844 @default.
• W1976547998 hasConceptScore W1976547998C2779889926 @default.
• W1976547998 hasConceptScore W1976547998C2908647359 @default.
• W1976547998 hasConceptScore W1976547998C50522688 @default.
• W1976547998 hasConceptScore W1976547998C530470458 @default.
• W1976547998 hasConceptScore W1976547998C71924100 @default.
• W1976547998 hasConceptScore W1976547998C72563966 @default.
• W1976547998 hasConceptScore W1976547998C84606932 @default.
• W1976547998 hasConceptScore W1976547998C99454951 @default.
• W1976547998 hasIssue "4" @default.
• W1976547998 hasLocation W19765479981 @default.
• W1976547998 hasLocation W19765479982 @default.
• W1976547998 hasOpenAccess W1976547998 @default.
• W1976547998 hasPrimaryLocation W19765479981 @default.
• W1976547998 hasRelatedWork W1976547998 @default.
• W1976547998 hasRelatedWork W2064540422 @default.
• W1976547998 hasRelatedWork W2109502540 @default.
• W1976547998 hasRelatedWork W2111168836 @default.
• W1976547998 hasRelatedWork W2113958163 @default.
• W1976547998 hasRelatedWork W2260015316 @default.
• W1976547998 hasRelatedWork W2411216460 @default.
• W1976547998 hasRelatedWork W4239467322 @default.
• W1976547998 hasRelatedWork W605272443 @default.

• next